These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

439 related items for PubMed ID: 8411259

  • 1. Elevation of multiple serum markers in patients with stage I ovarian cancer.
    Woolas RP, Xu FJ, Jacobs IJ, Yu YH, Daly L, Berchuck A, Soper JT, Clarke-Pearson DL, Oram DH, Bast RC.
    J Natl Cancer Inst; 1993 Nov 03; 85(21):1748-51. PubMed ID: 8411259
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. OVX1 as a marker for early stage endometrial carcinoma.
    Xu FJ, Yu YH, Daly L, Anselmino L, Hass GM, Berchuck A, Rodriguez GC, Soper JT, Clarke-Pearson DL, Hollis D.
    Cancer; 1994 Apr 01; 73(7):1855-8. PubMed ID: 8137210
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Macrophage colony-stimulating factor as a tumor marker for epithelial ovarian cancer.
    Suzuki M, Ohwada M, Aida I, Tamada T, Hanamura T, Nagatomo M.
    Obstet Gynecol; 1993 Dec 01; 82(6):946-50. PubMed ID: 8233270
    [Abstract] [Full Text] [Related]

  • 8. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.
    Hurteau JA, Woolas RP, Jacobs IJ, Oram DC, Kurman CC, Rubin LA, Nelson DL, Berchuck A, Bast RC, Mills GB.
    Cancer; 1995 Nov 01; 76(9):1615-20. PubMed ID: 8635066
    [Abstract] [Full Text] [Related]

  • 9. Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection.
    Berek JS, Bast RC.
    Cancer; 1995 Nov 15; 76(10 Suppl):2092-6. PubMed ID: 8635006
    [Abstract] [Full Text] [Related]

  • 10. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions.
    Skates SJ, Horick N, Yu Y, Xu FJ, Berchuck A, Havrilesky LJ, de Bruijn HW, van der Zee AG, Woolas RP, Jacobs IJ, Zhang Z, Bast RC.
    J Clin Oncol; 2004 Oct 15; 22(20):4059-66. PubMed ID: 15381683
    [Abstract] [Full Text] [Related]

  • 11. Clinical evaluation of circulating serum sialyl Tn antigen levels in patients with epithelial ovarian cancer.
    Kobayashi H, Terao T, Kawashima Y.
    J Clin Oncol; 1991 Jun 15; 9(6):983-7. PubMed ID: 1851822
    [Abstract] [Full Text] [Related]

  • 12. Increased serum levels of macrophage colony-stimulating factor in ovarian cancer.
    Xu FJ, Ramakrishnan S, Daly L, Soper JT, Berchuck A, Clarke-Pearson D, Bast RC.
    Am J Obstet Gynecol; 1991 Nov 15; 165(5 Pt 1):1356-62. PubMed ID: 1957862
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Serum level of macrophage colony-stimulating factor as a marker for gynecologic malignancies.
    Suzuki M, Ohwada M, Sato I, Nagatomo M.
    Oncology; 1995 Nov 15; 52(2):128-33. PubMed ID: 7854772
    [Abstract] [Full Text] [Related]

  • 15. Studies on angiogenesis in the benign and malignant ovarian neoplasms with the use of color and pulsed Doppler sonography and serum CA-125, CA-19.9, CA-72.4 and vascular endothelial growth factor measurements.
    Czekierdowski A.
    Ann Univ Mariae Curie Sklodowska Med; 2002 Nov 15; 57(1):113-31. PubMed ID: 12898913
    [Abstract] [Full Text] [Related]

  • 16. New tumor markers: CA125 and beyond.
    Bast RC, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshin A, Menon U, Jacobs I, Lu K.
    Int J Gynecol Cancer; 2005 Nov 15; 15 Suppl 3():274-81. PubMed ID: 16343244
    [Abstract] [Full Text] [Related]

  • 17. Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass.
    Hogdall EV, Høgdall CK, Tingulstad S, Hagen B, Nustad K, Xu FJ, Bast RC, Jacobs IJ.
    Int J Cancer; 2000 Nov 20; 89(6):519-23. PubMed ID: 11102897
    [Abstract] [Full Text] [Related]

  • 18. Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and TAG 72.3.
    Jacobs IJ, Oram DH, Bast RC.
    Obstet Gynecol; 1992 Sep 20; 80(3 Pt 1):396-9. PubMed ID: 1495694
    [Abstract] [Full Text] [Related]

  • 19. Soluble tumor necrosis factor receptors and CA 125 in serum as markers for epithelial ovarian cancer.
    Onsrud M, Shabana A, Austgulen R.
    Tumour Biol; 1996 Sep 20; 17(2):90-6. PubMed ID: 8658018
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.